Literature Review: A Sustained-Release Dihydrocapsaicin Microneedle Patch for Diabetic Wound Regeneration and the Role of Triton X-100 in Immunofluorescence Permeabilization

Home

Product Application

October 30, 2026

Clicks：73

Literature Review: A Sustained-Release Dihydrocapsaicin Microneedle Patch for Diabetic Wound Regeneration — and the Role of Triton X-100 (abs9149) in Immunofluorescence Permeabilization

1. Publication Overview

• Title: Sustained-Release Ulcer-Protective Microarray Patch With Dihydrocapsaicin for Diabetic Wound Regeneration

• Journal: Exploration (Wiley; 2026 latest IF = 30.4, CiteScore = 32.8; JCR Q1 across multidisciplinary, nanomaterials and bioengineering categories; open access)

• DOI: 10.1002/EXP.20250129 (2026)

2. Core Conclusions

The study constructed an MN-MOF@DHC composite microneedle patch that addresses three major clinical challenges of diabetic wounds in a single platform: oxidative stress overload, persistent chronic inflammation and defective angiogenesis.

• Ce-MOF exhibits dual SOD/CAT nanozyme activity, providing long-lasting clearance of wound ROS; its porous carrier structure enables steady release of dihydrocapsaicin (DHC) over 28 days, overcoming the poor aqueous solubility and rapid in vivo clearance of free DHC.

• In vitro: significantly reduced endothelial oxidative damage and apoptosis, promoted the phenotypic switch of macrophages from pro-inflammatory M1 to reparative M2, and enhanced endothelial migration and tube formation.

• In vivo: using two animal models (full-thickness dorsal wound in rats and diabetic foot ulcer), the MN-MOF@DHC group achieved essentially complete wound closure by day 16, with significantly better collagen deposition and neovascular/mature vessel density than all control groups.

• Material advantages: adequate mechanical strength to penetrate thickened diabetic skin, controllable degradation and high biosafety, offering a multifunctional transdermal delivery strategy for the full course of diabetic foot repair.

3. Role of the Absin Reagent

Absin Triton X-100 (abs9149) supported the entire mechanistic validation workflow, from in vitro cell assays to in vivo tissue analysis. It underpinned a standardized detection chain spanning cell permeabilization, ROS quantification, apoptosis detection, immune phenotyping and vascular marker staining, ensuring data reproducibility and statistical reliability.

4. Background and Scientific Question

Clinical burden of diabetic foot ulcers (DFU). With 529 million people living with diabetes worldwide, DFU is a severely disabling and life-threatening complication. Current clinical options remain limited:

• Pathological vicious cycle. The high-glucose environment generates abundant advanced glycation end products; ROS accumulate continuously in the wound, causing mitochondrial damage and endothelial apoptosis. Macrophages remain locked in the M1 pro-inflammatory phenotype, VEGF expression is suppressed, angiogenesis is blocked, and the inflammatory/proliferative/remodeling phases become disordered, greatly prolonging healing.

• Limitations of conventional therapy. Increasing antibiotic resistance; conventional dressings lack bioactivity; growth factors have extremely short half-lives; free DHC suffers from poor solubility, low bioavailability and rapid metabolism.

• Shortcomings of conventional microneedles. Limited drug loading, insufficient mechanical strength to penetrate thickened diabetic skin, no intrinsic ROS-scavenging capacity, and drug delivery without synergistic repair function.

Central question of the study. Can a Ce-based ROS-scavenging nanozyme MOF and DHC be integrated into a GelMA microneedle to build a single patch combining transdermal penetration, 28-day sustained release, endogenous antioxidant activity, immune reprogramming and pro-angiogenic regeneration — simultaneously breaking through the oxidative, inflammatory and vascular barriers of DFU?

5. Overall Research Design

The work follows a three-stage closed loop: material synthesis and physicochemical characterization → in vitro cellular mechanism → in vivo efficacy in two wound models.

1. Material synthesis and characterization. Ce-UiO-66 MOF was synthesized hydrothermally and loaded with DHC; composite microneedles were fabricated by UV photocrosslinking in 10% substituted GelMA. SEM/TEM/XRD/FTIR, nanozyme activity assays, in vitro release, mechanical/swelling/degradation and skin penetration tests were performed.

2. In vitro cellular mechanism. (i) Antioxidant and anti-apoptotic: TBHP-induced oxidative injury in HUVECs with ROS, mitochondrial membrane potential and apoptosis pathway analysis; (ii) immune regulation: LPS-induced M1 polarization with verification of M1→M2 reprogramming; (iii) pro-angiogenic: endothelial migration, tube formation and vascular marker immunofluorescence. All fluorescence staining steps used abs9149 for cell permeabilization.

3. In vivo validation. Type 2 diabetic rat dorsal wound and diabetic foot ulcer models were established; wound healing rate, H&E/Masson histology, tissue ROS, macrophage phenotyping and vessel density were quantified.

6. Module-by-Module Findings

Module 1 — Material characterization. Ce-MOF particles measured approximately 86 nm with a crystal structure matching the literature and concentration-dependent triple radical scavenging activity. MN-MOF showed greater mechanical strength than pure GelMA and could penetrate thickened diabetic skin. MN-MOF@DHC achieved 28-day sustained release, with microneedles degrading controllably over 16–20 days, matching the wound healing cycle. Nanozyme radical colorimetric assays were quantified using an Absin micro-volume colorimetric kit at 405/450/550 nm.

Module 2 — Antioxidant and anti-apoptotic effects in vitro. TBHP exposure caused substantial ROS accumulation, collapse of mitochondrial membrane potential and markedly increased apoptosis. MN-MOF@DHC markedly reduced ROS and alleviated mitochondrial damage and apoptosis, with downregulation of pro-apoptotic and upregulation of anti-apoptotic proteins, outperforming single-treatment groups.

Key protocol (abs9149, immunofluorescence, section 2.18 of the original text). Cells were fixed with 4% paraformaldehyde, washed with PBS, then incubated for 30 min at room temperature in PBS containing 0.1% abs9149 (Triton X-100). This gently solubilizes the phospholipid bilayer, allowing fluorescent probes and apoptosis antibodies to enter the cell and bind their targets. Blocking, primary antibody incubation and imaging followed.

Product advantage. A mild non-ionic detergent that preserves mitochondrial and apoptotic protein antigen conformation, giving stable fluorescence signal and clear inter-group statistical differences.

Module 3 — Macrophage M1/M2 polarization. After LPS-induced M1 polarization in RAW264.7 cells, iNOS (M1) and CD206 (M2) immunofluorescence, together with ELISA and qPCR, showed that MN-MOF@DHC significantly downregulated M1 markers and upregulated reparative M2 markers, with elevated IL-4/IL-10/IL-13 and increased Arg1/Mrc1 expression. For macrophage chamber slides, 0.1% abs9149 in PBS was applied for 30 min at room temperature after fixation to expose intracellular iNOS and CD206 epitopes.

Module 4 — Endothelial migration and angiogenesis. In TBHP-injured HUVECs, Transwell migration and Matrigel tube formation assays showed that the MN-MOF@DHC group reached a migration rate of 64.7% with the highest number of tubular networks, alongside significantly upregulated CD31 and VEGF. Permeabilization with 0.1% abs9149 fully exposed intracellular CD31 and VEGF for fluorescent semi-quantification.

Module 5 — Full-thickness dorsal wound healing in diabetic rats. Type 2 diabetes was induced in SD rats by high-fat diet plus STZ, and a 15 mm full-thickness dorsal skin defect was created. Wound closure was photographed on days 0/4/8/12/16. MN-MOF@DHC gave the fastest healing, with nearly 90% closure by day 12 and essentially complete healing by day 16; H&E sections showed complete re-epithelialization and thicker granulation tissue.

Module 6 — In vivo antioxidant, anti-inflammatory and anti-apoptotic verification. On 20 µm frozen sections, DHE staining for tissue ROS and immunofluorescence for iNOS/CD206/Bax were performed. Frozen sections were permeabilized with 0.1% abs9149 in PBS for 15–30 min to breach tissue lipid barriers and fully expose deep wound antigens, ensuring uniform ROS, inflammation and apoptosis fluorescence. The MN-MOF@DHC group showed the weakest DHE signal, reduced iNOS, elevated CD206 and the lowest Bax expression, fully reproducing the in vitro mechanism at tissue level.

Module 7 — Collagen deposition and mature vessel formation. Masson's trichrome staining and CD31 immunohistochemistry plus CD31/α-SMA dual fluorescence showed the highest collagen deposition, regularly arranged fibers, and significantly greater neovascular and mature vessel density in the MN-MOF@DHC group, indicating coordinated activation of the VEGF/Ang-1 pathway.

Module 8 — Diabetic foot ulcer model. A 6 mm ulcer was created on the hind paw of diabetic rats. Healing kinetics mirrored those of the dorsal wound: the MN-MOF@DHC group achieved essentially complete healing by day 16 with orderly granulation tissue, complete re-epithelialization and significantly increased mature vessel density, confirming suitability of the microneedle for clinically relevant diabetic foot lesions.

7. Summary: The Absin Reagent Portfolio in This Study

• abs9149 Triton X-100 — the single universal permeabilization reagent for all immunofluorescence and immunohistochemistry in the study, compatible with adherent cells and 20 µm animal frozen sections; mild permeabilization preserves antigen integrity, underpinning M1/M2 phenotyping, endothelial and vascular staining, oxidative stress and apoptosis imaging.

• Oxidative stress detection system (DCFH-DA / MitoSOX / JC-1 / DHE) — precise multi-scale ROS quantification at cell, mitochondrial and tissue levels.

• Apoptosis tools (TUNEL kit; cleaved caspase-3, Bax, Bcl-2 antibodies) — full elaboration of the molecular pathway by which the material protects endothelium and blocks oxidative apoptosis.

• Immune phenotyping and vascular antibodies (iNOS / CD206 / CD31 / VEGF / α-SMA) — simultaneous in vitro and in vivo verification of anti-inflammatory reprogramming and pro-angiogenic efficacy.

Together these reagents provide a complete closed-loop solution for this high-impact diabetic wound regeneration study: permeabilization → oxidative stress → apoptosis → immune regulation → angiogenesis.

Contact Absin

Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

Absin Bioscience Inc.

worldwide@absin.cn